Case Control Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Dec 14, 2016; 22(46): 10210-10218
Published online Dec 14, 2016. doi: 10.3748/wjg.v22.i46.10210
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Trial design. HBV: Hepatitis B virus; CHB: Chronic hepatitis B; HBeAg: Hepatitis B envelope antigen; ULN: Upper limit of normal; ALT: Alanine aminotransferase; PegIFNα-2a: Pegylated interferon-α-2a; ETV: Entecavir; Qd: Quaque die; Po: Peros.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Hepatitis B surface antigen levels in patients in the PEGylated interferon α-2a group and the entecavir group across therapy. HBsAg: Hepatitis B surface antigen; ETV: Entecavir.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Change in hepatitis B surface antigen levels during PEGylated interferon α-2a sequential therapy. HBsAg: Hepatitis B surface antigen.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Proportion of patients in different hepatitis B surface antigen level groups during pegylated interferon α-2a sequential therapy. HBsAg: Hepatitis B surface antigen.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 The hepatitis B envelope antigen seroconversion proportion after treatment baseline at different levels of hepatitis B surface antigen at week 24 during pegylated interferon α-2a sequential therapy. HBsAg: Hepatitis B surface antigen.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 The proportion of hepatitis B surface antigen loss after treatment with pegylated interferon α-2a at different levels of hepatitis B surface antigen at week 24. HBsAg: Hepatitis B surface antigen.